01) Bohlen B, Franzen D (May 19, 2024) Cardiac Damage After SARS-CoV2 Infection. Cureus 16(5): e60641. doi:10.7759/cureus.60641
02) Bohlen B, Bohlen H, Brugada P. Patient specific LQT.3 cardiomyocytes can be used for clinical drug safety assesments. Conference: Belgian Society of Cardiology - Modern cardiology in the picture. February 2019. DOI:10.13140/RG.2.2.15197.26087
03) Bohlen, D. Franzen (Köln). Kardiale Langzeitfolgen nach COVID-19 Infektion. P751. DGK Herztage 2022